HIV/AIDS Therapy
Reports describe recent advances in HIV/AIDS therapy research
Published in AIDS Weekly, February 21st, 2005
Study 1: Amdoxovir plus inosine monophosphate dehydrogenase inhibitors are active against wild-type and drug-resistant HIV-1 variants.
According to a study from the United States, "Amdoxovir [(-)-beta-D-2,6-diaminopurine dioxolane (DAPD)] is a nucleoside analogue reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) replication.
"DAPD is deaminated by adenosine deaminase to the guanosine analogue dioxolane guanosine (DXG), which is subsequently phosphorylated to the corresponding 5' triphosphate (DXG-TP)....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2005-02-21)
More Articles from AIDS Weekly
- HAART Monitoring
HPLC/UV effective for therapeutic antiretroviral drug monitoring - HIV/AIDS Pathogenesis
Improved control of HIV-2 infection may relate to contribution of CD4 response - HIV/AIDS Research
Annexin II may be new target for prevention of HIV-1 infection - HIV/AIDS Therapy
Curcumin inhibits acetylation of HIV Tat by p300 as well as virus proliferation - HIV/AIDS Therapy
P-TEFb kinase inhibitor flavopiridol inhibits HIV transcription elongation - Alcohol Use
Many alcohol-dependent HIV patients need assistance adhering to medications - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
